|
gptkbp:instance_of
|
gptkb:Clinical_Trials
|
|
gptkbp:aims_to_improve
|
major adverse cardiovascular events
|
|
gptkbp:completed
|
gptkb:2017
|
|
gptkbp:conducted
|
multiple countries
|
|
gptkbp:contributes_to
|
understanding of lipid-lowering therapies
|
|
gptkbp:critical_analysis
|
understanding cardiovascular risk factors
|
|
gptkbp:focuses_on
|
cardiovascular outcomes
|
|
gptkbp:has_a_follow-up_period_of
|
up to 5 years
|
|
gptkbp:has_a_primary_endpoint_of
|
cardiovascular death
|
|
gptkbp:has_a_secondary_endpoint_of
|
hospitalization for unstable angina
|
|
gptkbp:has_exhibited_at
|
major cardiology conferences
|
|
gptkbp:has_implications_for
|
gptkb:Health_Insurance
cholesterol management guidelines
|
|
gptkbp:has_influenced
|
clinical practice in cardiology
|
|
gptkbp:has_led_to
|
new treatment protocols
|
|
gptkbp:has_provided_evidence_for
|
long-term safety of evolocumab
|
|
gptkbp:has_shown_that
|
evolocumab significantly lowers LDL cholesterol
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
FOURIER trial
|
|
gptkbp:investigates
|
gptkb:evolocumab
|
|
gptkbp:involves
|
27,564 participants
patients on statin therapy
|
|
gptkbp:is_a_double-blind_study_involving
|
random assignment of participants
|
|
gptkbp:is_a_key_study_for
|
understanding PCSK9 inhibitors
|
|
gptkbp:is_a_multi-center_trial_involving
|
hundreds of sites
|
|
gptkbp:is_a_pivotal_trial_for
|
gptkb:PCSK9_inhibitors
|
|
gptkbp:is_associated_with
|
improved patient outcomes
reduced stroke rates
|
|
gptkbp:is_cited_in
|
numerous research articles
|
|
gptkbp:is_compared_to
|
evolocumab to placebo
|
|
gptkbp:is_considered
|
a landmark study
|
|
gptkbp:is_displayed_in
|
benefits in high-risk populations
|
|
gptkbp:is_funded_by
|
gptkb:pharmaceuticals
|
|
gptkbp:is_influential_in
|
the development of new drugs
|
|
gptkbp:is_led_by
|
gptkb:Dr._Steven_Nissen
|
|
gptkbp:is_part_of
|
the ODYSSEY program
the evolution of cardiovascular therapies
the evolution of lipid management strategies
the ongoing research in cardiovascular medicine
|
|
gptkbp:is_recognized_by
|
its contribution to clinical research.
|
|
gptkbp:is_referenced_in
|
medical textbooks
|
|
gptkbp:is_relevant_to
|
patients with atherosclerotic cardiovascular disease
|
|
gptkbp:measures
|
low-density lipoprotein cholesterol
|
|
gptkbp:published_in
|
gptkb:New_England_Journal_of_Medicine
|
|
gptkbp:registration
|
gptkb:Clinical_Trials.gov
|
|
gptkbp:showed
|
reduction in heart attack rates
|
|
gptkbp:sponsored_by
|
gptkb:Amgen
|
|
gptkbp:started_in
|
gptkb:2013
|
|
gptkbp:uses
|
randomized controlled trial design
|
|
gptkbp:was_a_demonstration_of
|
significant reduction in LDL levels
|
|
gptkbp:was_initiated_to_address
|
high residual cardiovascular risk
|
|
gptkbp:bfsParent
|
gptkb:Repatha
|
|
gptkbp:bfsLayer
|
5
|